PRMT5 and neoplasm: The PRMT5 inhibitor PF-06939999 inhibited the proliferation of non-small cell lung cancer (NSCLC) in cells and animal models and dose-dependent reduced symmetrical dimethylarginine (SDMA) levels.330 Another PRMT5 inhibitor, JNJ-64619178, has shown long-term PRMT5 inhibition and potent anti-tumor effect in lung, pancreatic, and hematological tumors.